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Summary In a population-based study serum sialic acid level was examined in relation to subsequent
development of central nervous system (CNS) tumours (229 cases). Significantly increased sialic acid concen-
tration was found in men with a malignant CNS tumour diagnosed within 8 years of analysis, compared with
corresponding matched controls. These findings suggest that the tumour existed at the time of examination
which is supported by a negative linear association between sialic acid level and the time from screening to
tumour diagnosis.
According to several studies, neoplastic transformation leads
to elevated serum sialic acid concentration, which has been
explained by increased release in the circulation of sialic
acid-rich cell surface glycoproteins and glycolipids (Henn &
Gressner, 1987; Marth et al., 1988), or by increased output of
acute phase proteins as a result of unspecified secondary
inflammatory reaction (Weiss et al., 1979; Turner et al.,
1985).
Only a few studies aiming at investigating the sialic acid
concentration as a brain tumour marker have been under-
taken (Weiss et al., 1979; Kakari et al., 1984; Marth et al.,
1988; Flaschka et al., 1990). All used a case-control design
with sialic acid determination after the diagnosis. Two of
them identified a difference in mean serum sialic acid concen-
tration between patients with benign and malignant brain
neoplasms (Marth et al., 1988; Flaschka et al., 1990). Direct
comparison between men and women was however not made
in any of the above studies.
The aim of the present investigation was to assess whether
serum sialic acid concentration is related to the occurrence of
CNS tumours in both men and women. Special emphasis was
given on differences between benign and malignant
tumours.
Materials and methods
In 1962-65 a general health survey was undertaken among
the total population aged 25 years or older in four Mid-
Swedish geographical districts. Altogether 97,468 persons
participated (77.0% of the target population). Details of
recruitment and screening methods used are given elsewhere
(National Board of Health and Welfare, 1971; Lindberg et
al., 1991).
All survey participants passed through a medical examina-
tion with measurement of blood pressure, weight and height,
and laboratory determination of different parameters. In the
present study, data on total serum sialic acid concentration
was used. The serum samples, collected under non-fasting
conditions, were chilled in ice and sent overnight to the
laboratory for analysis which was performed in an automatic
multiple analyser (AutoChemist). The method of Hess et al.
was used in 1962 (Hess et al., 1957) and Svennerholm's
method in 1964-65 (Svennerholm, 1957).
In Sweden all identified tumours of the nervous system
(benign as well as malignant) are mandatorily reported to the
National Cancer Registry. It is estimated that 96% of all
diagnosed cancers are reported and this proportion is higher
(98%) for the cases with histologically confirmed diagnosis
(Mattson & Wallgren, 1984). Survey data were matched with
this register in order to collect information on new cases of a
CNS tumour (any brain or intraspinal neoplasm including
those of the meninges) in the study population during
1962-1985. Cases without a histologically verified and
classified diagnosis and with tumours diagnosed before the
time of examination were excluded. Based upon histological
classification, all remaining cases were subsequently separat-
ed into two groups -benign or malignant CNS tumours
(Table I).
With a nested case-control design, five controls for each
case were randomly selected from the whole study population
after stratification for sex, age at screening (5-year groups)
and time (year and month) of sialic acid determination, the
latter to neutralise the possible impact of differing laboratory
methods as well as laboratory drift.
The 24 years' follow up period was divided into three
equal intervals (<8, 8-15 and ) 16 years). The duration
between sialic acid determination and tumour notification
was defined as lag period and was divided into the same
intervals as the follow up period.
Differences between means of sialic acid concentration in
cases and controls were evaluated by analysis of variance
(ANOVA). The relation between serum sialic acid level and
lag period for the different CNS tumour groups was assessed
by linear and nonlinear regression analysis. Statistical signi-
ficance was assumed at P<0.05. All tests were two-tailed.
Results
A total of 296 persons with a CNS tumour were identified
from the cancer register. Of these, 48 (16%) were excluded as
they lacked histological typing and 19 (6%) because they
were diagnosed before the sialic acid determination.
Thus, the present study included a total of 229 cases - 118
(52%) men and 111 (48%) women with a corresponding
proportion of controls
- 590 and 555 respectively. As shown
in Table I, of all tumours 124 (54%) were classified as benign
and 105 (46%) as malignant. Of the cases with a malignant
tumour 66 (63%) were in men and 39 (37%) were in women.
In both genders the majority of these tumours were ast-
rocytomas grade III-IV; 62 (94%) among men and 35 (90%)
in women. Among the benign tumours, astrocytoma grade
I-II and meningioma comprised together 41 (79%) of the
male cases and 60 (83%) of the female.
Table II shows mean serum sialic acid concentrations by
lag interval, malignancy and gender, compared with their
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Table I Number (%) of CNS tumours by histological diagnosis
Benign CNS tumours n (%) Malignant CNS tumours n (%)
Astrocytoma grade I-I11 31 (25) Astrocytoma grade III-IVa 97 (92)
Meningioma 70 (57) Malignant meningioma 1 (1)
Neurinoma 15 (12) Malignant neurinoma 4 (4)
Ependymoma 1 (<1) Malignant ependymoma 1 (1)
Choroid plexus papilloma 2 (2) Neuroblastoma 1 (1)
Craniopharyngioma 2 (2) Suspect malignant glioma 1 (1)
Hemangioma 3 (2)
Total 124 (100) Total 105 (100)
aAstrocytomas have been graded histologically according to the criteria ofKernohan
(Kernohan et al., 1949).
Table II Mean (standard deviation) serum sialic acid concentration measured at
initial examination, by lag period for different CNS tumour groups and gender
compared with corresponding controls (matched for sex, age at screening and time
of examination)
Sialic acid concentration (mgdl-')
Lag period Benign Malignant
(years) CNS tumours n Controls CNS tumours n Controls
Men
<8 69.9 (6.2) 12 70.4 (8.5) 73.3 (8.0)a 26 68.9 (7.3)
8-15 68.6 (11.9) 23 69.4 (9.6) 67.2 (6.3) 29 68.4 (6.6)
16 69.8 (7.2) 17 69.2 (8.3) 66.8 (7.3) 11 69.0 (9.9)
Women
<8 72.3 (11.4) 26 70.4 (8.9) 71.9 (10.5) 15 71.2 (8.9)
8-15 70.4 (8.9) 31 69.4 (8.3) 68.4 (7.2) 12 68.0 (6.6)
>16 69.5 (6.0) 15 69.2 (8.8) 73.6 (7.9) 12 69.5 (7.4)
ap <0.01.
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Figure 1 Age adjusted serum sialic acid concentration measured
at initial examination in men with diagnosed malignant CNS
tumour by lag period.
matched controls. As seen, among men the total serum sialic
acid level was significantly higher for cases with a malignant
tumour diagnosed during the first lag period (P<0.01). In
both genders the results for malignant tumours were not
altered after repeating the tests including only cases with
astrocytoma. Among men with diagnosed malignant CNS
tumour, 58 (88%) died from this neoplasm during the follow-
up period and thxe proportion was almost equal in women
-34 (87%). The mean survival (+ s.d.) after tumour diag-
nosis was 0.5 ± 0.7 years for men and 0.7 ± 1.4 years for
women.
Figure 1 shows a plot of serum sialic acid values (adjusted
for age at determination) in men with diagnosed malignant
CNS tumour by lag period, the latter with inverted (negative)
values. A negative linear association with the slope
0.48 mg dl-n yeard d (P = 0.004) was identified. The coefficient
of determination R2 was 12% and this was not improved
neither after fitting an exponential
polynomial equation.
nor a second degree
Discussion
Much attention has been devoted to study serum sialic acid
concentration in tumour patients with the aim of evaluating
its qualities as a tumour marker. However, as recently sum-
marised, this parameter is considered less applicable for
screening or diagnosis, but more suitable for monitoring
disease progression and response to treatment (Waters et al.,
1992).
The increased serum sialic acid level in tumour patients has
been explained by a spontaneous release ('shedding') of aber-
rant sialic acid-containing cell surface glycoconjugates.
Because of their probable importance for the main qualities
of transformed cells (disturbed cell-cell recognition and cell
adhesion, invasiveness and metastatic potential), it has been
suggested that these cell surface changes may be triggered by
specific oncogene activation (Singhal & Hakamori, 1990). In
that case it would be reasonable to conclude that this process
starts at a relative early stage of tumorigenesis and has a
continuous character, i.e. increases steadily with tumour
growth, which may explain the difference between benign and
malignant neoplasms.
The unspecified secondary reaction leading to increased
output of acute phase proteins may also be of some
significance for the sialic acid elevation in tumour patients.
Thus, the mean levels of the major sialic acid-rich acute
phase proteins (al-acid glycoprotein, a,-antitrypsin and hap-
toglobin) are significantly increased in patients with gliomas
compared to healthy individuals (Weiss et al., 1979).
No study has so far presented data on sialic acid concent-
ration measured before tumour diagnosis. The present inves-
tigation shows significantly increased serum sialic acid level
in a group of men among whom a malignant CNS tumour
was diagnosed during a period of 8 years after health
examination with sialic acid measurement. The data suggest
that the tumour already existed at the time of screening,CNS TUMOURS AND SERUM SIALIC ACID 427
without clinical manifestations. This presumption is sup-
ported by the negative linear association between serum sialic
acid concentration at screening and lag period.
The observed gender dissimilarities could be related to
differences in the level of sex steroids in men and women.
There are data on the presence of specific steroid hormone
receptors in CNS tumours and on possible tumour growth
stimulation effect of progesterone, by still unknown
mechanisms (Roelvink et al., 1987; von Schoultz et al., 1990).
The role of estrogens, however, is more uncertain and may
differ from that of progesterone.
The tumour cases occurring during the first lag period
(0-8 years), were diagnosed before the CT era, which gives
place for possible misclassification of the astrocytomas, con-
cerning both the benign and malignant forms, due to his-
tological sampling error. Such misclassification is a source of
error which would weaken the significance of the difference
mentioned above, as would also errors connected with the
reliability of single serum sialic acid measurement and used
methods of analysis. Thus it is reasonable to assume that the
received results exist despite possible errors of classification
and measurement and not because of them.
The study was supported financially by the Faculty of Medicine at
Lund University and Varmland County Council, Sweden.
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